Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma
Pegfilgrastim on Day +3 Compared to Day +1 for Patients With Refractory or Relapsed Aggressive Lymphoma Receiving Salvage Chemotherapy - a Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Liat Vidal-Fisher, MD
- Phone Number: 972-50-4065313
- Email: vidallit@yahoo.com
Study Locations
-
-
-
Petah Tikva, Israel, 49100
- Rabin Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adult patients (age 18 years or above)
- Refractory or relapsed aggressive lymphoma, including Hodgkin's and non-Hodgkin's lymphoma
- Candidate for salvage chemotherapy. Salvage chemotherapy includes one of the following regimens: Ifosfamide, etoposide, vincristine (ICE), Cisplatin, cytarabine, and dexamethasone (DHAP), Etoposide, methylprednisolone, cytarabine, cisplatin (ESHAP). Chemotherapy dose reduction will be allowed.
- Chemotherapy with or without immunotherapy
- Therapy in hospital or at the outpatient clinic
Exclusion Criteria:
- Indolent lymphoma; we will exclude patients with transformed lymphoma.
- Treatment with GCSFs for the primary disease (e.g. aplastic anemia, MDS).
- Uncontrolled infection
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Pegfilgrastim +1
Pegfilgrastim will be given 24 hours (day +1) after completion of salvage chemotherapy
|
Other Names:
|
|
EXPERIMENTAL: Pegfilgrastim +3
Pegfilgrastim will be given 72 hours (day +3) after completion of salvage chemotherapy
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Febrile neutropenia
Time Frame: 30 days
|
Number of participants with fever and neutropenia
|
30 days
|
|
Neutrophil count <500/ mcL
Time Frame: day 8 to 10
|
Number of participants with neutrophil count below 500 /mcL
|
day 8 to 10
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: 30 days
|
Number of participants who died by day 30
|
30 days
|
|
Neutrophil count <100/ mcL
Time Frame: day 8 to 10
|
Number of patients with neutrophil count below 100/ mcL
|
day 8 to 10
|
|
Number of febrile days
Time Frame: 30 days
|
a febrile day defined by at least one documented temperature measurement >38ºC
|
30 days
|
|
Development of clinically documented infections (CDI), microbiologically-documented infections (MDI) and clinically-significant bloodstream infections (BSI), not present at the time of randomization
Time Frame: 30 days
|
Number of participants with CDI, MCI or BSI.
CDI, MDI and BSI will be defined in accordance with the CDC surveillance definitions for healthcare-associated infections
|
30 days
|
|
Hospitalization
Time Frame: 30 days
|
Number of hospitalization days of each participant (excluding days of hospitalization for chemotherapy)
|
30 days
|
|
Adverse events
Time Frame: 30 days
|
ECOG common toxicity criteria grading Number of patients with an adverse event (AE).
Number of patients with grade 3-4 AE
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PEGFIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.